SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?


To: tommysdad who wrote (5262)9/4/1998 11:14:00 AM
From: Joe E.  Respond to of 6136
 
I notice Vertex is moving up sharply today. They of course have a potentially competitive drug to Viracept. Here is a posting on the SI VERTEX board yesterday (I have no idea about its veracity, but the timing is interesting):

<<To: David Witwer (189 )
From: David Witwer
Thursday, Sep 3 1998 12:54PM ET
Reply # of 190

Stock is moving up a little. What is worth watching is its price moves starting about
now. As I mentioned in an earlier post, Glaxo was to submit an abstract on phase III
results to gain admission as a "late breaker" to a conference starting Sept. 24. So, a
small group of conference planners now have, at least, the four primary variables from
the study including viral log decline and participant drop out rate. It will be interesting to
see how fast the results, good or bad, get into the stock's price given that the abstract
should be confidential information.>>



To: tommysdad who wrote (5262)9/4/1998 1:23:00 PM
From: Peter Church  Respond to of 6136
 
I think you can't take agph's fall too personally. It's just sinking with the tide. McCamant mentions several other biotechs which have done worse but have excellent prospects: isip, axph, imcl, icos.

Does anyone follow McCamant and have a sense of his stock picking ability? He also says that biotechs are not cyclical. But, how are some of these unprofitable companies going to survive if capital gets scarce? By being swallowed by larger fish, I guess.

bioinvest.com